Sustainability Report 2014-2015 - Roche Latin America
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
Roche Latin America
Sustainability
Report
2014-2015
Coordination, editing, and content verification Find out more:
Edelman
Graphic design and layout
2MCINE
Data and photos provided by
Roche Global and Roche country affiliates
Roche Latin America
Produtos Roche Químicos e Farmacêuticos S.A.
Av. Engenheiro Billings, 1.729 – Jaguaré
CEP 05321-900 – São Paulo/SP, Brazil
All Rights Reserved
Partial or total reproduction of this report is prohibited without
the prior authorization of F. Hoffmann-La Roche Ltd Our global sustainability website at:
http://www.roche.com/responsibility.htm
Support with identification, provision and accuracy of content:
Argentina Ecuador
Productos Roche S. A. Q. e I. Roche Ecuador S.A.
Rawson 3150, (B1610BAL), Ricardo Rojas, Tigre Av. 10 de Agosto N36-239 y Naciones Unidas, Casilla: 1711-06185
Província de Buenos Aires, Argentina Quito, Ecuador
Brazil Mexico
Produtos Roche Químicos e Farmacêuticos S.A. Productos Roche S. A. de C.V.
Av. Engenheiro Billings, 1.729 – Jaguaré Cerrada de Bezares No. 9
CEP 05321-900 – São Paulo/SP, Brazil Col. Lomas de Bezares
11910, Mexico, D.F.
Central America and the Caribbean
Productos Roche S.A. Peru
Zona Franca Ultrapark, Edificio 4 Roche Perú
La Aurora, Heredia, Costa Rica San Isidro, Dionísio Derteano 144 of. 1301
Lima, Peru
Chile
Roche Chile Ltda. Uruguay
Av. Cerro el Plomo 5630, Piso 12. Las Condes. Roche International Ltd
Santiago, Chile WTC - Torre 4, Piso 5, Luis Bonavita, 1266
Montevideo, Uruguay
Colombia
Productos Roche S.A. Venezuela
Carrera 44 No. 20-21 Produtos Roche S.A.
Bogotá, Colombia Edificio Roche, Av. Diego Cisneros, Los Ruices
Caracas, Venezuela
4 Roche Latin America 2014-2015 Sustainability Report Roche Latin America 2014-2015 Sustainability Report 5
Welcome to our
Sustainibility Report
2014-2015
Contents
1. This Report . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9 8. Colombia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 97
Roche Colombia at a Glance . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 98
2. Global Overview . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11 Healthcare in Colombia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 99
Roche at a Glance . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11 Roche in Colombia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 99
Roche Group Profile. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15 Sustainability Initiatives . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 101
Sustainability Strategy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15
9. Ecuador . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 109
3. Latin America . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25 Roche Ecuador at a Glance . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 110
Roche Latin America at a Glance . . . . . . . . . . . . . . . . . . . . . . . . . 26 Healthcare in Ecuador . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 111
Healthcare in Latin America . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29 Roche in Ecuador . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 111
Roche in Latin America . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31 Sustainability Initiatives . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 113
Sustainability Initiatives . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33
10. Mexico . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 119
4. Argentina. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45 Roche Mexico at a Glance . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 120
Roche Argentina at a Glance . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46 Healthcare in Mexico. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 121
Healthcare in Argentina . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47 Roche in Mexico. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 121
Roche in Argentina . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47 Sustainability Initiatives . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 123
Sustainability Initiatives . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 49
11. Peru . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 131
5. Brazil . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 59 Roche Peru at a Glance . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 132
Roche Brazil at a Glance . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 60 Healthcare in Peru . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 133
Healthcare in Brazil . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 61 Roche in Peru . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 134
Roche in Brazil . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 61 Sustainability Initiatives . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 135
Sustainability Initiatives . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63
12. Uruguay . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 143
6. Central America and the Caribbean . . . . . . . . . . . . . . . . . . . . . . . 73 Roche Uruguay at a Glance . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 144
Roche Central America and the Caribbean at a Glance . . . . . . . 74 Healthcare in Uruguay . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 145
Healthcare in Central America Roche in Uruguay . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 145
and the Caribbean . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 75 Sustainability Initiatives . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 147
Roche in Central America and the Caribbean. . . . . . . . . . . . . . . 75
Sustainability Initiatives . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 77 13. Venezuela . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 157
Roche Venezuela at a Glance . . . . . . . . . . . . . . . . . . . . . . . . . . . . 158
7. Chile . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 85 Healthcare in Venezuela . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 159
Roche Chile at a Glance . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 86 Roche in Venezuela . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 159
Healthcare in Chile . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 87 Sustainability Initiatives . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 161
Roche in Chile . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 87
Sustainability Initiatives . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 89
6 Roche Latin America 2014-2015 Sustainability Report Roche Latin America 2014-2015 Sustainability Report 7
This Report
At Roche, we are dedicated to doing good business that contrib- Roche’s most recent sustainability report, 2015 Global Report,(1)
utes to a better world. Everything we do as a company is guided follows the GRI G4 standards, and its content is guided by an
by our commitment to scientific rigor, unassailable ethics, and updated global materiality assessment. The regional office of
access to medical innovations for all. We value transparency Roche in Latin America(2) follows the Group’s approach, and
and ethical management, and public reporting on our activities our second regional Sustainability Report is informed by the
and results is an important tool for promoting both. The Group GRI G4 methodology.
has been publishing a sustainability report for more than 10
years and has adopted the guidelines of the Global Reporting This report covers Roche’s economic, social, and environmental
Initiative (GRI). impacts in Latin America for the two-year period from January 1,
2014 to December 31, 2015. The content covers the Pharmaceu-
ticals Division in the 10 affiliates comprising the regional group:
Argentina, Brazil, Central America and the Caribbean, Chile,
Colombia, Ecuador, Mexico, Peru, Uruguay, and Venezuela. The
data highlighted in this report are based on key performance in-
dicators in all of the listed affiliates.
We value transparency Roche believes sustainability is an on-going journey of continu-
ous improvement. This report reflects a moment in time on that
and ethical management, journey, and Roche is committed to strengthening and expanding
its sustainability management processes and tools in the future.
and public reporting on
our activities and results (1)
Roche Annual Report 2015: www.roche.com/gb15e.pdf
is an important tool for (2)
In this report, “Roche in Latin America” only refers to its Pharmaceuticals Division.
promoting both.
8 Roche Latin America 2014-2015 Sustainability Report Roche Latin America 2014-2015 Sustainability Report 9
Global Overview
Roche at a Glance
A global leader in innovation A sustainable company A great workplace
Roche is the world’s largest biotech- Roche is committed to business Roche is driven by a shared set of
nology company and a leader in re- practices that are sustainable, ethi- values including integrity, the cour-
search-focused healthcare. cal and responsible to create long- age to reach beyond boundaries
term value. and a passion for what we do.
+100
Countries
#1
in biotech
#1
in oncology and
#1
in hospital markets
in vitro diagnostics
48.1
billion CHF(3) in sales
9.3
billion CHF in
91,747
Employees
R&D investment (full-time equivalents)
29
Roche medicines on WHO
70
new medical entities in
40%
Women
Essential Medicines List clinical development in management roles
25,000,000
Patients treated
+300,000
Patients in clinical trials
with one of Roche’s top 25 selling products
2015 data
Figures include Pharmaceutical and Diagnostics divisions.
For further information: www.roche.com
(3)
Swiss francs
10 Roche Latin America 2014-2015 Sustainability Report Roche Latin America 2014-2015 Sustainability Report 11
Who we are
Innovation: it’s in our DNA. At Roche we have always worked across As the world’s largest biotech company, we develop breakthrough
disciplines and geographies to drive scientific discovery and redefine medicines, improving the standard of care across oncology, im-
what is possible to improve patients’ lives. munology, infectious diseases, ophthalmology and neuroscience.
We are also the world leader in the in vitro diagnostics business.
We work towards understanding how diseases differ down to the This track record allows us to build lasting and meaningful part-
molecular level in order to develop new tests and medicines that nerships across the world with research academia and public
prevent, diagnose and treat diseases that matter and bring them to healthcare institutions.
the patients who need them. With our combined strengths in diag-
nostics and pharmaceuticals, our personalised healthcare strategy We remain dedicated to the highest standards of quality, safety and
aims to fit the right treatment to the right patient. integrity. Our legacy is based on respect for the individual, as well
as the communities and the world we live in.
Our values
Integrity starts with me. Discovery starts with passion.
We are consistently open, honest and genuine. We use our drive and commitment to energise, engage and in-
spire others.
Just as we expect it from ourselves and our colleagues, society
expects that we live by high standards of integrity. Integrity starts Above all, our passion is to improve patients’ lives, and it is this
with being honest with oneself and understanding one’s own passion that fuels our determination and enables us to persevere,
strengths and weaknesses. It is also about interacting with others often over many years. Passion can express itself in highly visible
in an open, genuine way. That is a must for building a strong re- ways – such as an enthusiastic speech or a persuasive presentation.
lationship of trust with anyone, whether inside or outside Roche. It can also be low key – such as persistently repeating an experi-
We must act ethically and honestly at all times. ment over and over again to determine whether an unexpected
result was just an error or possibly an important new discovery.
Success starts with courage.
We are entrepreneurial, taking risks, experimenting and reaching
beyond boundaries.
Our business and strategy takes us often into uncharted territory.
This also means that we must have the courage to take appropri-
Above all, our passion ate risks in order to succeed. This means we need to think like
entrepreneurs and be prepared to try new ways of doing things
is to improve patients’ even if we are convinced that the traditional ways are right. We
may not always feel comfortable about taking a minority view or
lives, and it is this expressing criticism. Yet if we don’t speak up, we run the risk of
not tackling necessary changes, whether out of complacency or
passion that fuels our an ill-conceived desire for harmony. Being courageous will en-
sure we can remain successful and stay ahead in the long run.
determination and
enables us to persevere,
often over many years.
12 Roche Latin America 2014-2015 Sustainability Report Roche Latin America 2014-2015 Sustainability Report 13
Roche Group Profile
Roche is a global healthcare pioneer advancing science for human- To date the Roche Group has helped to improve peoples’ health and
ity. We are committed to bringing these advances to everyone who quality of life in more than 150 countries all over the world. As a
needs them, no matter where they live. And this is our promise: to world leader in research on healthcare products, the company op-
care about this generation, as well as the ones to come. erates exclusively in the fields of pharmaceuticals and diagnostics.
The founding families continue to hold the majority stake in the
Founding Roche in 1896, more than 100 years ago in Switzerland, company. This stability allows for a tradition of sustainable think-
our company’s founder, Fritz Hoffmann, turned a pioneering idea ing, allowing us to learn from setbacks and pass down lasting value
into reality: that a partnership between business and science can for patients and society.
improve peoples’ lives. Expanding globally, our founders tackled
obstacles, worked across disciplines and cultures and embraced
risks. This is still how we transform lives, provide cures, comfort
and hope, to make a difference in the health of millions.
Sustainability Strategy
Innovation for Patients – Access to Healthcare
The Sustainable Development Goals adopted by the Member In addition, the Roche Group invests heavily in cutting edge
States of the United Nations in September 2015 include the pro- research and development (R&D) as part of its commitment to
motion of ‘good health and well-being.’ As a global healthcare innovation for patients. Core R&D investments in 2015 totalled
company, Roche has the opportunity to actively commit and 9.3 billion CHF, or 19.4% of sales with pharmaceuticals repre-
contribute to achieving this important societal goal. In this vein, senting a large portion of this corporate commitment.
Roche has developed five primary pillars that focus on patients
and improved access to healthcare: Delivering Innovation, In- External innovation is also crucial to Roche’s strategy of bringing
creasing Disease Awareness, Strengthening Healthcare Infra- critical treatments to patients in areas of unmet medical need. We
structure, Improving Affordability and Supporting Local Patient currently manage over 200 partnerships worldwide. Our teams
Organisations. of experts work closely with internal R&D groups to gauge needs
and gaps. At the same time, they track emerging companies on
academic advances and on other collaborative opportunities,
Delivering Innovation screening thousands of potential partners a year before selecting
those that will truly help Roche advance drug discovery and de-
Roche’s most powerful contribution in this area lies in develop- velopment in an impactful way.
ing tests and medicines to meet some of the most urgent medical
needs worldwide. It is here that we explore ideas, face setbacks
and relentlessly pursue new approaches to make true advances Increasing Disease Awareness
against disease. Our employees remain dedicated to transforming
science into breakthrough medicines and diagnostics to improve Improving access to medicines and diagnostics is vital, but still
the life of each patient in the best way possible. not enough to improve global healthcare. A holistic approach of
health education and awareness is also critically important to a
In pharmaceuticals, Roche is a global leader in oncology, tack- patient’s long-term outcome. As such, we support local commu-
ling melanoma, breast, ovarian, cervical and lung cancer, diffi- nity partners to run screening, awareness and counselling pro-
cult-to-treat indolent non-Hodgkin lymphoma and many others. grammes, and help empower people worldwide with the knowl-
Roche has made important contributions to significantly lower- edge to safeguard and manage their own health.
ing cancer mortality rates globally over the past 20 years. In 18
years, Roche has developed 11 cancer treatments with proven Through our collaborative efforts with patient groups, hospitals
survival benefit to patients. and health organisations around the world, we help increase
awareness of diseases such as cancer, rheumatoid arthritis, hep-
Beyond oncology, Roche is forging innovative treatments in im- atitis, osteoporosis and diabetes. We also conduct screening pro-
munology, particularly multiple sclerosis (MS). MS affects ap- grammes for the early detection of these diseases and publish
proximately 2.3 million people worldwide; thus, effective treat- information on newsletters, magazines and other publications
ment and diagnosis can have impact at scale, improving quality aimed at helping people make healthy choices and changing be-
of life for those around the world. haviours to prevent disease.
14 Roche Latin America 2014-2015 Sustainability Report Roche Latin America 2014-2015 Sustainability Report 15
Innovation for Patients – Access to Healthcare (cont.)
Additional information is also developed specifically for patients, We believe that all players are required — public authorities, In a complex global market, we understand that the value of our Supporting Patient Organisations
families and caregivers who operate counselling services to help non-governmental stakeholders, patient organisations, local products, the ability of healthcare systems and individuals to pay
them understand diseases and the proper use of our products. communities, the healthcare industry and others — to work for them varies greatly across different regions. To address this Roche takes patient engagement very seriously and endeavours
They can also find details on the latest information about tests closely together to improve health and well-being. As a global issue, we are exploring new pricing models that are tailored to to support patient organisations’ objectives wherever possible.
and treatment options on a variety of websites that Roche has healthcare company, Roche plays a key role and shares a respon- the dynamics of each healthcare system, rather than a uniform We believe that together, we can spark meaningful change for
helped develop. sibility to tackle the challenges of improving health outcomes. pricing structure. the future of human health. Today our interactions with patient
That’s why we are committed to working with partners at the local groups are multifaceted and range from funding organisations
level to overcome barriers and improve access to tests and medi- Through this unique approach, we hope to find solutions that and building capacity to organising meetings and supporting ad-
Strengthening Healthcare Infrastructure cines for all patients. allow us to continue to invest in the research and development vocacy. The International Experience Exchange for Patient Or-
of products that can transform patients’ lives, while balancing ganisation (IEEPO), Roche’s largest global patient organisation
Roche believes a multi-stakeholder approach to access and infra- the needs of our stakeholders and our commitment to improv- meeting, was held in Munich in 2015 and focused on the vital
structure is key to getting innovation to the patients who need Improving Affordability ing access. role of patient organisations. A record total of 189 delegates from
treatment most. Many Roche-developed products can make 41 countries attended IEEPO 2015, and agreed that the potential
healthcare delivery more efficient by improving the mode of ad- When a new product is brought to market, we work closely with role patients can play in research, clinical trial design and recruit-
ministration, or reducing the time patients spend in the hospital. governments, insurers and other healthcare providers to deter- ment, HTA and other aspects of drug development and access,
In addition, advances in science have led to personalised health- mine its value. This enables us to demonstrate the value of the could and should increase significantly.
care that focuses on providing the right treatment for the right product to patients, their families, healthcare professionals, pay- R&D investments in
patient. Unlike previous one-size-fits-all methods, personalised ers and society in general, in order to gain appropriate reimburse- We believe in delivering medical solutions urgently, even as we
healthcare recognises that each patient is unique, and by using ment. We consider numerous factors when determining value, 2015 totalled 9.3 billion develop innovations for the future. That’s why we are committed
specific diagnostic tests, doctors can now predict how well a pa- including: the effectiveness of our medicine or diagnostic; other to working with partners at the local, regional and global level to
tient responds to treatment for certain diseases or conditions. medicines or diagnostics used to treat or test the same disease; fu- CHF, or 19.4% of sales. overcome barriers and improve access to tests and medicines for
These tests also enable physicians to determine the best dosage ture investment needed to discover new medicines and diagnos- all patients.
and duration of treatment. tics; how to ensure that our products get to the people who need
them; and the affordability of our product to healthcare systems
and individuals.
16 Roche Latin America 2014-2015 Sustainability Report Roche Latin America 2014-2015 Sustainability Report 17
Great Workplace for Employees Responsible and Compliant Partners
As a science and innovation-driven company, Roche’s most im- Roche is committed to increasing the representation of key lead- Compliance is our license to operate and serves as a foundation to All Roche employees are expected to follow the integrity guide-
portant global asset is our people. We are committed to provid- ers with established and developing regional experience and build and maintain trust with our stakeholders. Stakeholder en- lines outlined in the Roche Group Code of Conduct. In addition
ing the best possible working environment so they can thrive. providing opportunities for our employees to work in different gagement is a key pillar of Roche’s comprehensive sustainability to employees, Roche’s suppliers and service providers are ex-
Globally, we are focused on expanding diversity and inclusion, environments. We are also committed to increasing the represen- management process. This allows us to identify and prioritise ma- pected to adhere to similar standards. Our Roche Supplier Code
providing leadership opportunities for employees and providing tation of women in key leadership positions. In 2015 we made terial issues, like at our yearly Sustainability Forum, where more of Conduct is included in contracts and we offer an e-Learning
a healthy, productive work environment that cares for employees. progress on this goal, with women now accounting for at least than 80 internal stakeholders and external experts discuss inno- programme to help our suppliers and service providers increase
23% of leaders in key leadership positions and for 40% of man- vations in the supply chain, how to improve access to healthcare their knowledge and understanding of Roche’s expectations and
Our five-year goals for people management globally include: agement overall. and elevate sustainability reporting at the partner level, and how of industry standards. Roche also maintains a stringent process to
• A 30% increase in the representation of women in key leader- to enhance employee engagement. qualify and audit current and new suppliers and service provid-
ship roles Roche also offers a variety of work-life balance and wellness pro- ers. In 2015 we conducted more than 1,000 audits of global and
• A 30% increase in the representation of people with estab- grammes to employees including opportunities to work remotely, local suppliers and service providers.
lished and developing region experience allowances for family leave, health and wellness education, bene-
• A top quartile ranking in overall employee engagement score, fits and flexible work schedules. Ensuring patient safety and the effectiveness of our medicinal
measured by the Global Employee Opinion Survey (GEOS) products is our top priority. We collaborate with regulatory agen-
Roche has consistently been recognised as one of the best com- In 2015 we conducted cies, monitor reports of adverse events experienced by patients
Diversity and inclusion are vital as the global marketplace is in- panies to work for. The company has been consistently awarded and communicate on our product safety activities.
creasingly connected. Our business is different across our divi- placement on several ‘Great Place to Work’ lists, including the more than 1,000 audits
sions and the world and employees who understand those dif- Fortune 100 best companies list, Working Mother magazine’s
ferences are critical to our success. An inclusive culture fosters 100 best companies list, and DiversityInc’s 25 most noteworthy of global and local
innovation by encouraging different perspectives, ideas and companies.
thinking styles. In 2015 we defined what diversity and inclusion suppliers and service
means to us and formalised the Diversity & Inclusion Practi-
tioners’ Network to ensure that leaders are aligned in the way we providers.
bring this commitment to life in our day-to-day business.
18 Roche Latin America 2014-2015 Sustainability Report Roche Latin America 2014-2015 Sustainability Report 19Supporting Communities Protecting the Environment
Roche is committed to global philanthropic activities including Safety, security, health and environmental protection are import- We measure our total environmental impact using the eco-bal-
community involvement, humanitarian projects, science, edu- ant and enduring issues in a changing world. At Roche we refer to ance metric developed by the Swiss Federal Office for the Envi-
cation, art and culture. We seek to support local communities activities that address these areas as SHE. We believe that protect- ronment. This metric provides us with a global view of how we
through long-lasting partnerships. Following natural disasters ing people and the environment isn’t just a legal or social obliga- are impacting the Earth’s ecosystems. Our strategic five-year goal
such as the 2015 Nepal earthquake and flooding in Malawi and tion, it’s integral to our operations. For that reason, we approach is to reduce our eco-balance by 10% by 2019.
Pakistan, Roche works with local partners to provide immedi- SHE with the same sense of responsibility – and just as method-
ate support with essential donations of medicines and long-term ically – as we do issues concerning product quality, productivity
support to help communities rebuild. Roche has provided finan- and cost efficiency.
Roche has provided cial support and donated millions of treatments for relief efforts,
including medical products to treat and prevent infectious dis- Prevention is a key element in all our activities. Our corporate
financial support and eases in the wake of natural disasters. policies and guidelines outline our commitments for ensuring the
safety of people and protecting the environment. We maintain
donated millions of Roche also has a long-standing philanthropic commitment in these standards by adhering to laws and regulations, by cooper- Protecting people and the
Malawi, Southeast Africa. Since 2003 Roche has supported ed- ating with authorities and by communicating openly and frankly
treatments for relief ucation programmes for HIV/AIDS-orphaned children in the about our activities. environment is integral to
region. Each year employees donate money and time as part of
efforts. Roche Children’s Walk reaching over 17,000 children in the re- Research and pharmaceutical and diagnostic manufacturing are our operations.
gion as well as 90 local communities globally over the past 12 dependent on natural resources, which are becoming increasing-
years of the programme. ly scarce. At Roche, our goal is to minimise our impact on the en-
vironment and to increase the use of renewable resources whilst
These are just a few ways we demonstrate our commitment to continuing to expand our global business. As part of our com-
the communities where we live, work and operate. Our goal is mitment toward sustainable development, we proactively seek to
to establish long-term partnerships by focusing on projects that employ new, more sustainable technologies and processes.
add lasting value to society at the global, regional and local levels.
20 Roche Latin America 2014-2015 Sustainability Report Roche Latin America 2014-2015 Sustainability Report 21Protecting the Environment (cont.) External Recognition
As a global player, Roche has the opportunity to reduce its impact Roche strives to implement the following strategy in its activi- Roche has been named to the CDP(4) A List, awarded as a CDP
on climate. We have prioritised energy efficiency and renewable ties — avoid, reduce, reuse, recycle, thermally destroy. We permit Climate Disclosure Leader, and in 2015 Roche became an Indus-
energy sourcing as two key ways to reduce our climate footprint. landfilling only as a last resort and, even then, only for inert ma- try Leader in Dow Jones Sustainability Index for the 7th consecu-
Since 2010 a total of 1,063 energy-saving projects have been com- terials such as slag or incineration ash. Depending on the avail- tive year(5). Our efforts were also recognised by Newsweek, which
pleted, yielding a reduction of approximately 127,000 tonnes of ability of suitable local waste-treatment plants, we may dispose of ranked Roche as the number 9 greenest company in the world’s Industry Leader
CO2 emissions and an estimated cost saving of CHF 27.6 mil- non-hazardous general waste in authorised landfills. Roche does 500 largest publicly-traded companies (by market capitalisation) for the 7th consecutive year
lion per year. Roche has also recently set a 10-year goal (2015– not accept landfilling of chemical waste or other hazardous ma- also in 2015. (According to Dow Jones Sustainability Index)
2025) to reduce energy intensity (gigajoule/employee) within our terials. In 2015 we set new goals for general and chemical waste
owned facilities and purchased energy consumed by us by 15%. reduction: reduce general waste per employee by 10% over a five-
By approximately 2050, we expect to reduce energy consumption year period and reduce landfilling of organic chemicals by 50%
per employee by approximately 50%, compared to 2005 baseline over a five-year period.
(4)
CDP is formerly the Carbon Disclosure Project
(5)
Dow Jones Sustainability Indices: www.sustainability-indices.com/
levels. Additionally, we plan to increase the proportion of sustain-
able energy use to 20% by 2020. Operationally, Roche is compliant with all local and regional laws
on environment, health, and safety and as such, we also focus on
For the pharmaceutical industry globally, poor quality water is re- environmental responsibility, compliance, prevention and reduc-
sulting in higher costs for purification and greater risk of product tion of occupational accidents and supply chain management as
contamination. The demand for fresh water is increasing and an part of a broad commitment to corporate responsibility. In Safe-
effective water management is crucial to avoid water scarcity. Our ty, Health and Environmental protection we employ 651 peo-
aim is to protect water resources by reducing the amount of water ple worldwide and 491 people in Security. Expert teams at each
consumption, recycling water where possible and purifying water Roche site identify risks and develop mitigation plans.
to protect water quality. Our 2015–2020 water goal is to reduce
consumption per employee by 10%, weighted according to the
water stress for a respective region.
22 Roche Latin America 2014-2015 Sustainability Report Roche Latin America 2014-2015 Sustainability Report 23Watch video here Latin America
“Distinguishing health journalism means promoting
quality information around a matter of fundamental
importance for society.” Jaime Abello Banfi
General Director of the Gabriel García Márquez
Foundation for New Ibero-American Journalism (FNPI)
At FNPI we work to promote excellence in journalism, and to In this context, journalists play the key educational role of help-
support the contribution reporters make to the development of ing generate a better understanding among the general public of
countries across Latin America and the Caribbean. In this spirit, complex health issues, raising awareness, and guiding people to-
since 2013 we have a collaboration project with Roche that con- wards better self-care for disease prevention. In this way, health
sists of a health journalism award. In this effort, the FNPI func- journalists become drivers of value and benefits for society.
tions as the technical secretariat, handling the entire process to
ensure its professionalism and independence. The main goal of the Roche Award for Health Journalism is to
contribute to communities across Latin America by recognizing
The issue of health is increasingly important and complex. It is and promoting good journalistic practices and quality coverage
no longer just about the traditional doctor-patient relationship, a of health topics. And at the same time, through workshops and
merely medical or scientific issue. Today, people are evermore af- the broadcasting of distinguished works, the award also looks
fected and concerned by healthcare, as it spreads across political, to open a space for discussion and knowledge-exchange, among
social and economic dimensions. journalists and between them, experts and other key stakehold-
ers. Above all, it is about driving attention and encouraging
high-quality information around a matter of critical and increas-
ing importance.
24 Roche Latin America 2014-2015 Sustainability Report Roche Latin America 2014-2015 Sustainability Report 25Roche Latin America São Paulo, Brazil 1930
at a Glance Headquarters Established
Women in
Headcount Women Key Positions
4,328 50.5% 42.9%
2014 2014 2014
4,335 51.2% 42.8%
2015 2015 2015
Turn Over Rate New Hires Internal Hires
13% 695 237
2014 2014 2014
13.6% 617 207
2015 2015 2015
Hours of Training
Total Hours of Training per Employee
53,882 12.4
2014 2014
96,123 22.2
2015 2015
Clinical Trials 2014 2015
Number of Clinical Studies 121 126
Environment 2014 2015
Energy Consumption (GJ) 493,097 512,104
Number of Active Sites 1,388 1,211
GHG Emissions (tons) 33,094 34,221
Number of Patients in Clinical Trials 4,677 3,751
Water Consumption (cubic meters) 74,317 117,456
General Waste Produced (tons) 460 425
Research & Development 2014 2015
Recycling (tons) 1,894 422
Investment in R&D (mCHF)(6) 97 89
Paper Consumption (tons) 1,382 93
Number of Employees in R&D 421 450 Investment in SHE (CHF)(7) 927,000 4,665,000
(Safety, Security, Health and Environment)
(6)
Million Swiss francs (7)
Investment figures in Swiss francs and also include the Diagnostics Division
26 Roche Latin America 2014-2015 Sustainability Report Roche Latin America 2014-2015 Sustainability Report 27The region currently spends 7.6%
of its gross domestic product on
healthcare and this number is
expected to increase 4.6% every
year through 2018
Healthcare in Latin America
Latin America has experienced rapid and stable growth in recent
years, resulting in increased healthcare spending in and govern-
ment attention to programmes that improve access to healthcare.
The region currently spends 7.6% of its gross domestic product
on healthcare(8) and this number is expected to increase 4.6% ev-
ery year through 2018.(9) Despite these investments, significant
challenges remain, including a lack of infrastructure and trained
professionals, low levels of education and awareness, affordabil-
ity difficulties and disparities between local private and public
healthcare systems.
Countries in Latin America vary widely on a number of factors
that impact the healthcare landscape, including economic devel-
opment, social and cultural standards, regulatory approaches,
health infrastructure and perspectives on intellectual property.
Healthcare treatments also vary greatly between the private and
public healthcare sectors throughout Latin America. These dis-
crepancies can be found across healthcare expenditures, income
levels and levels of government funding in the region, and are
particularly impactful for complex diseases like cancer.
As a result, the cancer mortality rate in Latin America is higher
than that in the United States and Europe,(10) despite the region’s
lower incidence rate. To address this issue, many countries are
looking for new ways to sustainably increase access to healthcare.
(8)
The Economist Intelligence Unit. Healthcare 2015
(9)
Deloitte. 2015 Global Healthcare Outlook
(10)
Lancet Oncology 2013. Planning Cancer Control in Latin America and the Caribbean
28 Roche Latin America 2014-2015 Sustainability Report Roche Latin America 2014-2015 Sustainability Report 29Roche in Latin America Roche has been a
Roche expanded to Latin America in 1930 with subsidiaries in dedicated partner with
Buenos Aires, Argentina and Rio de Janeiro, Brazil. As of 2015,
Roche Latin America operates in 23 countries with regional governments, physicians
headquarters in São Paulo, Brazil, and owns two manufacturing
plants in Mexico and Brazil. and patient associations
Each country in Latin America faces unique healthcare challeng- in Latin America for
es, and Roche’s commitment is as large and varied as the region
itself. Roche has been a dedicated partner with governments, more than 80 years, and
physicians and patient associations in Latin America for more
than 80 years, and understands regional variations well. This understands regional
experience helps us develop a nuanced approach based on local
market conditions. variations well.
Roche’s presence in Latin America is characterised by a deep
commitment to driving healthcare development and improve-
ment. In 2014 and 2015, more than 200,000 patients across Lat-
in America were treated with our strategic products in oncology
and immunology. We are also one of the three fastest growing
pharmaceutical companies. This growth is primarily driven by
the increasing availability and demand for biological therapies.
In the last two years, more than 50 Roche biological medica-
tions were approved in the region for a wide variety of diseases,
ranging from the treatment of cervical cancer to the treatment of
HER2-positive breast cancer. Roche embraces its responsibility as
a leader in oncology and understands the unique challenges Latin
America faces when it comes to cancer awareness, prevention,
diagnosis and treatment.
30 Roche Latin America 2014-2015 Sustainability Report Roche Latin America 2014-2015 Sustainability Report 31Sustainability Initiatives
Access to Healthcare
Roche Latin America believes that every person who needs our to inadequacies in fundamental infrastructure, to political and
products should be able to access and benefit from them. For this financial barriers. Roche takes a multi-stakeholder approach,
to happen, several conditions need to be in place, including disease works to strengthen national cancer plans and partners within
awareness, adequate healthcare infrastructure and sufficient medi- healthcare systems to increase access to tests and medicines.
cal coverage. Roche is committed to tailoring solutions on a coun- Above all else, we work to elevate the patient voice to be sure our
try-by-country basis to fit each country’s unique needs. most important stakeholders are heard. Through these activities,
Roche supports the Group’s five primary pillars: Delivering In-
In Latin America, Roche works with a variety of partners across novation, Increasing Disease Awareness, Strengthening Health-
issues and geographies to ensure we are effectively addressing care Infrastructure, Improving Affordability and Supporting Lo-
problems ranging from lack of disease awareness or diagnostics, cal Patient Organisations.
Delivering Innovation
As the population’s average age and life expectancy increase, de- Research and Development:
mands on healthcare systems are growing exponentially. Health- In Latin America, Roche is developing an innovation network of
care costs are rising and innovative medicines are expensive to independent research and development centres. Roche invested
develop. At Roche we strive to provide our medicines to anyone 186 million CHF(11) in this network in 2014 and 2015, and has en-
who needs them, so we work closely with healthcare authorities gaged 450 employees thus far. In addition to the results of the tri-
and other stakeholders to develop solutions to bring our medi- als themselves, these efforts also benefit healthcare infrastructure
cines to more patients. and expand medical training, leading to higher quality patient
treatment in participating hospitals.
To foster innovation, Roche partners with a diverse network of
organisations in Latin America and around the world. In 2014- Clinical Trials:
2015 Roche Latin America was particularly focused on person- Roche Latin America developed 121 clinical studies in 2014, en-
alised healthcare and biotechnology. gaging 1,388 sites and 4,677 patients. In 2015 Roche developed
126 studies across 1,211 sites that involved 3,751 patients.
Personalised Healthcare:
Roche is a global leader in personalised healthcare and is known In 2014 our clinical studies produced great insight into combina-
for developing treatments that improve health standards and tion therapies. In HER2-positive metastatic breast cancer, a par-
quality of life for patients. At present, approximately half of Roche ticularly aggressive form of the disease, we found unprecedented
Latin America’s pharmaceutical projects are being developed in data on one drug, which, when combined with chemotherapy and
parallel with diagnostic tests, leading to solutions that aim to fit another treatment, increased survival time for patients to almost
the right treatment to the right patient. five years. Another study showed that when combining two drugs
for advanced melanoma, the risk of the disease advancing was cut
Biotechnology: in half. Roche now has over 30 different combination therapies in
Biotechnology is fostering considerable advances in the treatment its oncology pipeline.
of disease. Roche is currently the largest producer of medications
in the biotechnology industry, with the most sophisticated bio- Since 2012 the U.S. Food and Drug Administration (FDA) has
pharmaceutical production unit in the world that is responsible granted Breakthrough Therapy Designations to 12 indications of
for roughly 25% of global biological production capacity. Roche medicines, four of them in 2015 alone.
(11)
Swiss francs
32 Roche Latin America 2014-2015 Sustainability Report Roche Latin America 2014-2015 Sustainability Report 33Increasing Disease Awareness
At Roche, we recognize that raising awareness for health is just as
important to a patient’s well-being as proper diagnosis and treat-
ment. Greater public awareness of disease and symptoms can in-
crease prevention rates and help patients receive early, accurate
diagnoses. Throughout Latin America, we promoted and drove
awareness in 2014 and 2015 for a variety of diseases including
cancer, hepatitis, and cystic fibrosis, among others, across more
than 170 awareness campaigns.
Cancer Awareness:
To address high mortality rates for cancer across Latin America,
Roche offices throughout the region create and support various
awareness campaigns covering lymphoma, breast, ovarian, cer-
vical, colorectal, and lung cancers. These campaigns are devel-
oped to meet the unique needs of each country and they aim to
provide the public with proper information on prevention, early Roche Press Day:
diagnosis and treatment options through websites, leaflets, con- As journalists play a vital role in disseminating and deepening
ferences, forums, and the media. Beyond disseminating informa- public knowledge to increase awareness, prevention, and ear-
tion, Roche also leads local activities that involve the community, ly diagnosis of critical illnesses, we developed Roche Press Day
for example, local awareness walks to raise funds and awareness (RPD) in 2012. The event is hosted annually and seeks to pro-
for a specific disease. mote knowledge exchange and continued education for many
of today’s most serious diseases. Each year RPD brings togeth-
Breast cancer awareness month in October is an area of strong er journalists from all over Latin America and expert panelists
support across Roche Latin America and in addition to the activ- from around the world to discuss the latest scientific advances
ities mentioned, during the month some offices light their build- and health-related issues and trends in the region. The event also
ing pink to recognise patients and Roche’s commitment to the hosts the venue for recognizing the winners of the Roche Award
fight against the disease. for Health Journalism. The award, organised by the Foundation
for New Ibero-American Journalism (FNPI) and sponsored
by Roche Latin America, honours and promotes high-quality
health journalism.
Strengthening Healthcare Infrastructure Roche works to develop
Latin America faces a variety of complex healthcare challenges, programmes that transfer
ranging from lack of basic infrastructure and education for health
professionals to gaps in public policy and healthcare regulation. information and skills to
Roche aims to develop programmes that address these challenges
by driving efficiency in healthcare systems, promoting accessibil- local partners.
ity and supporting infrastructure improvements.
We believe sustainable solutions that meet the needs of the
healthcare sector must go beyond traditional philanthropic mod-
els. Wherever possible, Roche works to develop programmes
that transfer information and skills to local partners. With this in Diálogo Roche:
mind, we aim to provide benefits across the entire value chain and This is the company’s official website for sharing scientific infor-
focus our efforts on initiatives that strengthen education, boost lo- mation with healthcare professionals. It offers users relevant in-
cal infrastructure, support quality medicine production and dis- formation on health issues, clinical studies, medical advances and
tribution and reinforce public policies. We know success requires congresses, among others, to promote disease prevention. With
collaboration, and we work in partnership with key stakeholders more than 46,000 registered physicians, the website is currently
including the medical and scientific communities, governmental active in seven Latin American countries: Argentina, Brazil, Co-
agencies, research centres and healthcare professionals. lombia, Mexico, Paraguay, Peru and Uruguay.
34 Roche Latin America 2014-2015 Sustainability Report Roche Latin America 2014-2015 Sustainability Report 35Supporting Local Patient Organisations
At Roche we recognise and support the great work being done
by patient organisations to reduce barriers to healthcare and in-
crease patient access. Here are a few examples of collaborative
initiatives in this area:
“Patient Voices in Action”:
Roche launched “Patient Voices in Action” in 2013 to help pa-
tient organisations improve their leadership, management and
social action skills through an executive training programme in
partnership with the Health and Aging Foundation of the Au-
tonomous University of Barcelona. The first session was hosted
in Panama in 2013 and followed by online learning modules
throughout 2014, culminating in a final in-person meeting in
Costa Rica during 2015.
The introductory training session provided participating organ-
isations with a step-by-step itinerary for learning and practicing
social action skills. In the following e-learning opportunities, the
programme offered a “meeting point” for participants to discuss
needs and future challenges and share experiences, while also
offering knowledge and tools to improve their daily practices.
Through the course, participants could build their capacity to
communicate with healthcare and social agents and use resources
in a more effective way.
A total of 36 patient organisations from 11 countries participated
in the course, including: Argentina, Brazil, Chile, Colombia, Cos-
Improving Affordability ta Rica, Ecuador, Mexico, Panama, Peru, Uruguay and Venezuela.
Many of the organisations are dedicated to oncological patients
Healthcare realities and challenges vary significantly across and Patient Access in Latin America: Governance, Assessment Organised by Roche Regional Market Access Latin America and and other pathologies, including hepatitis and transplants.
within countries in Latin America. In recognition of these vari- Methodologies, and Evidence-Informed Decision Making in Global Health Policy teams in partnership with the Internation-
ables, Roche prioritises flexibility and tailors all programming to Health Policy al Society For Pharmacoeconomics and Outcomes Research
adapt to each market. We focus on the specific barriers to access Roche hosted a forum in 2015 that brought together 40 key stake- (ISPOR), the conversation aimed to ensure that all participants
in each area, which can include a combination of socioeconomic holders to discuss governance principles and methodologies for involved have a good understanding of how evidence-informed
factors, disease epidemiology, political commitment, healthcare reimbursement assessment decision-making in Latin America. decision making can improve overall health system performance,
funding, health insurance coverage and the quality of healthcare The participants included government officials, health technolo- as well as the trade-offs in applying different approaches when
infrastructure. Roche works alongside government agencies at gy assessment experts, patient group representatives, Roche rep- assessing the value of healthcare technologies and services for
the national, state and municipal levels to support and promote resentatives, and other key stakeholders (for example, therapeutic specific interventions.
responsive healthcare systems that address the specific needs of area experts, health economists and academics).
the population and reduce barriers to healthcare access. Following the event, Roche received 100% positive feedback from
participants, who expressed interest in further engagement on
Roche’s approach to pricing also reflects the varying needs of each this important topic. Two-thirds of respondents also mentioned
country in the Latin American region. Roche develops coun- that they view Roche as a credible voice on reimbursement as-
try-specific agreements that align with local needs, policies and Roche prioritises sessment methodologies in Latin America.
regulations. Currently we are piloting an assistance programme
to provide pharmaceuticals to the public healthcare system at flexibility and tailors A follow-up webinar with participants, including stakeholders
lower prices than market rate. Initially this pilot has focused on who could not participate in the forum due to other commit-
cancer, hepatitis C and other chronic disease treatments. Roche all programming to ments, was scheduled for 2016 to ensure continued dialogue and
also provides direct assistance programmes to subsidise payment strengthen relationships.
options for patients who are unable to afford health insurance. adapt to each market.
36 Roche Latin America 2014-2015 Sustainability Report Roche Latin America 2014-2015 Sustainability Report 37In 2015 Roche Latin
America provided a
Employees
total of 96,123 training
At Roche we believe success is driven by employees motivated
by a common purpose working in a culture of learning. Roche hours, which translates
in Latin America is committed to creating a stimulating, partic-
ipatory work environment and creates initiatives to build the ca- to 22.2 hours per
pacity, engagement, health and well-being of our employees. We
have invested in talent development, improved personnel man- employee.
agement tools and policies, and offered training sessions on a va-
riety of topics. In 2015 Roche Latin America was ranked among
the best companies to work in the Great Place to Work® survey.
Roche Latin America currently employs 4,335 people, of whom
51% are women and 49% men. Among key leadership positions,
121 are filled by women, comprising 42% of total positions.
Diversity and Inclusion:
Roche Leadership is committed to seven principles: taking a genu- Roche is committed to maintaining an environment where every-
ine interest in people; listening carefully, telling the truth, explain- one contributes to our mission of delivering innovative diagnos-
ing ‘the why;’ empowering and trusting people to make decisions; tics and developing life-saving treatments, regardless of gender,
discovering and developing the potential in people; striving for race, ethnicity, sexual preference or religious background. Diver-
excellence and extraordinary results; setting priorities and simpli- sity is a top priority for us, and we want to foster a workplace
fying work; and congratulating people for a job well done. Roche where diversity goes beyond visible differences to encompass a
also provides resources and trainings for leadership development, variety of educational backgrounds, professional knowledge,
as well as 360 degree feedback and performance management. personality types, thinking styles and life experiences. Emerg-
In 2015 Roche Latin America provided a total of 96,123 training ing markets, like Latin America, are the most important growth
hours, which translates to 22.2 hours per employee. driver for Roche in the next 5-10 years. As a result, Roche ac-
tively works to foster diverse leadership that represents the global
Roche 2014 Global Employee Opinion Survey (GEOS): make-up of our portfolio and encourages best-practice sharing
Our 2014 GEOS received an 80% employee engagement rate and across markets. Integrating a variety of perspectives is crucial to
confirmed our talent management approach is on the right track. developing new medicines and access programmes to address the
More than 80% of the employees surveyed said they would find it needs of customers and patients in Latin America and beyond.
hard leaving the company and that they would recommend it to a
friend seeking employment. Live Well at Roche:
In 2013 Roche launched the global “Live well. Find your balance”
According to the survey, Roche Latin America’s employees value programme, which includes a “Well-being week” for all employ-
the daily work and responsibilities given to each individual; the ees. Hosted at more than 100 Roche locations worldwide, Roche
feeling of accomplishment and the impact of their work; and are employees in all Latin American affiliates participated in Live
proud to work at Roche because of its reputation in the market. Well events. Each location puts its own spin on the week, offering
In 2015 Roche Latin The results of the survey were very positive, but we know we can unique programmes that promote health, relaxation, nutrition
do even better. Each affiliate in Roche Latin America is working to and exercise. Activities range from yoga classes to cooking work-
America was ranked implement programmes for continuous improvement. We deeply shops, massages, birthday celebrations and football matches.
value our dialogue with employees and recognise it as an invalu-
among the best able resource in our efforts to improve our business practices.
companies to work In addition to our own employees, Roche is deeply committed to
ethical employment across the entire region and supports pro-
in the Great Place grammes to fight child labour, forced labour and modern slave
labour practices in eight countries including Brazil, Nicaragua,
to Work® survey. Honduras, Mexico, Guatemala, Dominican Republic, El Salvador
and Costa Rica.
38 Roche Latin America 2014-2015 Sustainability Report Roche Latin America 2014-2015 Sustainability Report 39Governance We take our responsibilities
Organisational Structure: Ethics and Transparency: The Roche Code of Conduct: seriously in order to meet
The Roche Code of Conduct encompasses the Group’s Corporate
The Latin American Leadership Team (LLT) is responsible for Roche’s primary objective is to meet patients’ and healthcare pro- Principles, as well as the policies and references that guide the high standards of business
corporate governance and management to ensure business sus- fessionals’ needs for high-quality products and services. To meet conduct of all staff members in all regions where the company
tainability in the short and long term, and is organised to foster this objective, Roche must identify needs and problems in health- operates. Employees are encouraged to seek guidance when in ethics and integrity.
innovation and collaboration in an open and transparent manner. care and provide solutions. We take our responsibilities seriously doubt about the correct way to proceed in business, and to re-
This culture allows Roche to learn from both success and failure in order to meet high standards of business ethics and integri- port cases of possible issues involving compliance and ethics. The
and set meaningful goals for the future. ty. This is instrumental to our sustainable success, and hence to code also addresses situations of conflict of interest that must be
our ability to make a lasting impact on public health. Integrity at reported by executives. To help employees, the company has a
Roche means doing things right from the start. speak-up line to report potential compliance violations.
Executive Committees: Each country within Roche Latin
America has an Executive Committee, comprised of the Our commitment includes full respect for patients’ individual Supplier Engagement Programme:
country president, executives, and managers, that reports rights. We also build respect for the individual into all our work Roche’s goal is to be one of the top three companies in sustain- In Latin America we have conducted 140 supplier audits in the
to the regional Head. The purpose of this committee is to and for all members of the organisation, and apply our Corporate ability in the health industry. To achieve this, Roche needs a sup- last two years to ensure compliance with Roche and industry
ensure responsible management and organisational align- Principles in our relations with business partners. We are com- ply chain that supports and implements these same principles. codes and standards. All of our suppliers also receive training on
ment between each country affiliate and the Group. In cer- mitted to maintaining high ethical and social standards in our To this end, the company has maintained a Code of Conduct for our Code of Conduct and have to accept it in order to be one of
tain countries, such as Brazil, Roche also has Compliance business dealings, in our approach to medical science, and in our Suppliers since 2010 and expects every company or profession- our business partners. Suppliers who exceed expectations are also
and Sustainability Committees, which specifically address efforts to protect the environment and ensure good citizenship. al maintaining commercial relations with Roche to comply with recognized by Roche Latin America for their outstanding service
relevant issues in the country. We are committed to innovation and benchmarking our prin- this Code of Conduct. The Code provides guidance for suppliers as encouragement for all suppliers to perform their best.
ciples and achievements against the industry and best practice, on issues relating to sustainability with emphasis on its impor-
which includes transparent reporting. tance to Roche. Through the Code, the company requires its sup-
pliers to adhere to specific sustainability principles: ethics, em-
ployment, health and safety, environment, management systems,
innovation, economic sustainability, and diversity of suppliers.
40 Roche Latin America 2014-2015 Sustainability Report Roche Latin America 2014-2015 Sustainability Report 41You can also read
